Results 61 to 70 of about 655,218 (318)

Differentiated complex physical rehabilitation at the chronic obstructive disease of lights [PDF]

open access: yesPedagogìka, Psihologìâ ta Mediko-bìologìčnì Problemi Fìzičnogo Vihovannâ ì Sportu, 2011
General description of chronic obstructive disease of lights, classification and clinic is considered. The modern going is described near setting of rehabilitation facilities. It is well-proven that a medical physical culture at the diseases of breathing
Ruban L.A.
doaj  

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

open access: yesFEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto   +3 more
wiley   +1 more source

Long-acting beta2-agonists for chronic obstructive pulmonary disease.

open access: yes, 2013
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up.
Walters, JA   +5 more
core   +1 more source

Mixed‐class J‐domain protein scaffolds promote expanded aggregate handling and multivalent Hsp70 engagement during functional disaggregase assembly

open access: yesFEBS Letters, EarlyView.
Protein aggregates threaten proteostasis and cell health. In human cells, Hsp70–J‐domain protein‐based disaggregases remove aggregates, but how they assemble remains unclear. Our biochemical findings show that DNAJA2‐ and DNAJB1‐containing disaggregase scaffolds enhance luciferase aggregate targeting, and that Hsp70 recruitment by both J‐domain ...
Anna Szlachcic, Nadinath B. Nillegoda
wiley   +1 more source

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease.

open access: yes, 2011
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Developments in the understanding of COPD have led to standard guidelines for diagnosis, treatment, and spirometry assessments, which have in turn ...
James Donohue   +5 more
core   +1 more source

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. [PDF]

open access: yes, 2011
BACKGROUND: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Fabbri, Leonardo M.   +74 more
core   +1 more source

Primary Colon Lymphoma Presenting with Obstructive and Hemorrhagic Symptoms

open access: yesTurkish Journal of Colorectal Disease, 2019
Colorectal lymphomas comprise less than 1% of colorectal malignancies and 1% of non-Hodgkin lymphomas. Colonic lymphomas are usually diagnosed after surgical resection performed due to complications. Herein we present the management of a rare case of non-
Nidal İflazoğlu   +8 more
doaj   +1 more source

Obstruction Before the Obstruction [PDF]

open access: yesCirculation: Heart Failure, 2020
Timothy A. Joseph   +3 more
openaire   +2 more sources

OBSTRUCTION OF THE BOWELS. [PDF]

open access: yesJAMA: The Journal of the American Medical Association, 1898
" Obstruction of the bowels" is a technical phrase which implies a mechanical obstacle to the onflow of the intestinal contents. Its causes are various and the obstruction may be complete or partial, acute or chronic. It may occur at any portion of the intestinal tract from the duodenum to the rectum.
openaire   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy